Company intelligence / Profile preview

AltiMed Pharmaceuticals

Toronto, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

AltiMed Pharmaceuticals was a Canadian pharmaceutical company primarily focused on the marketing and distribution of generic drug products. Originally established as a joint venture between Mylan Laboratories and Apotex, the company played a significant role in the Canadian generic drug market during the 1990s. In 1998, Mylan Laboratories acquired the remaining 50% interest in the company to gain full control of its operations. Following the acquisition, AltiMed's business was integrated into Mylan's global infrastructure, which later became part of Viatris following the merger of Mylan and Upjohn.

Modalities: Small molecule
Industry: Biotech

Partnerships

ApotexMylan

Beyond the preview

Go deeper on AltiMed Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AltiMed Pharmaceuticals.

Explore the full profile